Recurrence of tuberculosis
https://doi.org/10.52888/0514-2515-2024-360-1-95-101
Abstract
The problem of tuberculosis reactivation after pulmonary tuberculosis is urgent, according to a review of the available literature. There are certain difficulties in the differential diagnosis between a true relapse and a re-infection. The incidence of tuberculosis reactivation varies considerably from country to country. There is no evidence in the literature of a modern, integrated approach to preventing pulmonary tuberculosis relapse. The COVID-19 pandemic has also increased the risk of TB reactivation. There is also a need to make changes in the order of hospital observation of TB patients, which will undoubtedly affect the frequency of tuberculosis relapses.
About the Authors
L. Sh. Ukumatshoeva
SEI “Avicenna Tajik State Medical University”, Department of Phthisiopulmonology
Tajikistan
Tajikistan
Ukumatshoeva Lalbegim Shozodaevna – Senior Lecturer,
Dushanbe.
O. I. Bobokhojaev
SEI “Avicenna Tajik State Medical University”, Department of Phthisiopulmonology
Tajikistan
Tajikistan
Dushanbe.
References
1. Abilbaeva A.A. Faktory, assotsiirovannye s razvitiem retsidiva tuberkuleza [Factors associated with the development of tuberculosis relapse]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2022, Vol. 100, No. 10, pp. 30-36.
2. Alekseenko S.N. Rannie retsidivy tuberkuleza legkikh – epidemiologicheskie i ekonomicheskie problemy [Early relapses of pulmonary tuberculosis - epidemiologic and economic challenges]. Sovremennye problemy nauki i obrazovaniya – Modern problems of science and education, 2019, No. 2.
3. Aliev S.P. Effektivnost vyyavleniya sluchaev tuberkulyoza sredi naseleniya g. Dushanbe Respubliki Tadzhikistan [Efficiency of tuberculosis case detection among the population of Dushanbe city of the Republic of Tajikistan]. Vestnik Avitsenny – Bulletin of Avicenna, 2018, Vol. 21, No. 4, pp. 56-61.
4. Alliluev A.S. Mashinnoe obuchenie v prognozirovanii retsidivov u bolnykh tuberkulezom s mnozhestvennoy lekarstvennoy ustoychivostyu [Machine learning in predicting relapse in multidrug-resistant tuberculosis patients]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2021, No. 99 (11), pp. 27-34.
5. Bobokhodzhaev O.I. K voprosu o reaktivatsii tuberkulyoznogo protsessa [To the question of reactivation of tuberculosis process]. Vestnik Avitsenny – Bulletin of Avicenna, 2018, Vol. 20, No. 2-3, pp. 320-324.
6. Guseynaliev N.V. Sovershenstvovanie vyyavleniya tuberkuleza v uchrezhdeniyakh pervichnogo meditsinskogo zvena i ego vliyanie na pokazatel zabolevaemosti [Improvement of tuberculosis detection in primary health care facilities and its impact on morbidity rate]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (10), pp. 41-46.
7. Zorkaltseva E.Yu. Klinicheskie proyavleniya retsidivov tuberkuleza u bolnykh VICH-infektsiey [Clinical manifestations of tuberculosis relapses in HIV-infected patients]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (6), pp. 32-35.
8. Korzh E.V. Effektivnost lecheniya i retsidivy tuberkuleza u bolnykh VICh-infektsiey s glubokoy immunosupressiey, nachavshikh antiretrovirusnuyu terapiyu [Treatment efficacy and tuberculosis recurrence in profoundly immunosuppressed HIV-infected patients started on antiretroviral therapy]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (10), pp. 11-18.
9. Kulchavenya E.V. Retsidivy urogenitalnogo tuberkuleza [Recurrences of urogenital tuberculosis]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (10), pp. 19-22.
10. Nechaeva O.B. Sostoyanie i perspektivy protivotuberkuleznoy sluzhby Rossii v period COVID-19 [Status and prospects of the Russian TB service in the period of COVID-19]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (12), pp. 7-19.
11. Cterlikov S.A. Vliyanie aktivnogo vyyavleniya sluchaev tuberkuleza na rezultaty lecheniya vzroslykh patsientov s tuberkulezom legkikh [Impact of active TB case detection on treatment outcomes of adult patients with pulmonary tuberculosis]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2021, No. 99 (7), pp. 33-40.
12. Cardona P. Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective study. PLoS One, 2018, No. 13 (7), pp. e0200150.
13. Chen Q. Recurrence Is a Noticeable Cause of Rifampicin-Resistant Mycobacterium tuberculosis in the Elderly Population in Jiangxi, China. Frontiers in Public Health, 2019, No. 7, pp. 182.
14. Crisan-Dabija R. Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes. Canadian Respiratory Journal, 2020, pp. 1401053.
15. Cudahy P.G.T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases, 2020, No. 20, pp. 789.
16. Dedefo M.G. Treatment Outcomes of Tuberculosis Retreatment Case and Its Determinants in West Ethiopia. The Open Respiratory Medicine Journal, 2019, No. 13, pp. 58–64.
17. Folkvardsen D.B. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases, 2020, No. 20 (1), pp. 789.
18. Folkvardsen D.B. Recurrent tuberculosis in patients infected with the predominant Mycobacterium tuberculosis outbreak strain in Denmark. New insights gained through whole genome sequencing. Infection, Genetics and Evolution, 2020, No. 80, pp. 104169.
19. Furtado I. Getting back on the road towards tuberculosis elimination: lessons learnt from the COVID-19 pandemic. The Brazilian Journal of Pulmonology and international databases, 2021, No. 47 (2), pp. e20210123.
20. Maghradze N. Classifying recurrent Mycobacterium tuberculosis cases in Georgia using MIRU-VNTR typing. PLoS One, 2019, No. 14 (10), pp. e0223610.
21. Mirsaeidi M. Patients at high risk of tuberculosis recurrence. International Journal of Mycobacteriology, 2018, No. 7, pp. 1-6.
22. Reid M.J.A. Building a tuberculosis-free world while responding to the COVID-19 pandemic. Lancet, 2020, No. 396 (10259), pp. 1312-1313.
23. Sahu S. Recovering from the Impact of the Covid-19 Pandemic and Accelerating to Achieving the United Nations General Assembly Tuberculosis Targets. International Journal of Infectious Diseases, 2021, No. 113 (1), pp. S100-S103.
24. Shao Y. Relapse or Re-Infection, the Situation of Recurrent Tuberculosis in Eastern China. Frontiers in Cellular and Infection Microbiology, 2021, No. 11, pp. 638990.
25. WHO Global tuberculosis report 2022. Geneva, World Health Organization Publ., 2022.
26. WHO Information Note. COVID-19: considerations for tuberculosis care. Geneva, 2021. 15 p.
27. Wingfield T. Surveillance of tuberculosis cases attributable to relapse or reinfection in London, 2002-2015. PLoS One, 2019, No. 14 (2), pp. e0211972.
28. Xie Z. Factors associated with diagnostic delay in recurrent TB. BMC Public Health, 2020, No. 20 (1), pp. 1207.
29. Zong Z. Relapse versus reinfection of recurrent tuberculosis patients in a national tuberculosis specialized hospital in Beijing, China. Frontiers in Microbiology, 2018, No. 9, pp. 1858.
Review
For citations:
Ukumatshoeva L.Sh., Bobokhojaev O.I. Recurrence of tuberculosis. Health care of Tajikistan. 2024;(1):95-101. (In Russ.) https://doi.org/10.52888/0514-2515-2024-360-1-95-101
Views:
233
Email this article 